A5007730796- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- HIV/AIDS drug development and treatment
- Long-Term Effects of COVID-19
- SARS-CoV-2 detection and testing
- Systemic Lupus Erythematosus Research
- Chronic Lymphocytic Leukemia Research
- Liver Disease and Transplantation
- Pharmaceutical industry and healthcare
- RNA Interference and Gene Delivery
- Liver Diseases and Immunity
- Biochemical and Molecular Research
- Animal Virus Infections Studies
- Lymphatic Disorders and Treatments
- Corporate Identity and Reputation
- Respiratory viral infections research
- Immunodeficiency and Autoimmune Disorders
- Drug-Induced Hepatotoxicity and Protection
- Renal Transplantation Outcomes and Treatments
- Securities Regulation and Market Practices
- Gastrointestinal disorders and treatments
- HIV Research and Treatment
Jan Kochanowski University
2022-2024
The COVID-19 pandemic proceeds in waves, with variable characteristics of the clinical picture resulting from evolution SARS-CoV-2 virus. This study aimed to compare epidemiological characteristics, symptomatology, and outcomes disease patients hospitalized for during periods different variants dominance. Comparing dominance preceding Delta variant, period was characterized by a higher share females, less frequent comorbidities among patients, age distribution. lowest need oxygen therapy...
Up to now, COVID‑19 caused more than 6 million deaths worldwide. So far, 5 variants of concerns have been identified, with Delta and Omicron being the subject our analysis.We aimed compare baseline characteristics outcomes patients hospitalized during predominance in Poland.The study population consisted 2225 divided into 2 groups depending on variant which they were infected corresponding period pandemic.During wave, median age was significantly lower (65 vs 73 years; P <0.001), cohort less...
Introduction With the introduction of highly effective and safe therapies with next-generation direct-acting antivirals (DAAs), that act without interferon, hepatitis C virus (HCV) infection remains only treatable chronic infectious disease.
The real-world effectiveness of molnupiravir (MOL) during the dominance Omicron SARS-CoV-2 lineage is urgently needed since available data relate to period circulation other viral variants. Therefore, this study assessed efficacy MOL in patients hospitalized for COVID-19 a clinical practice wave infections.
This study aimed to compare the clinical picture of COVID-19 in initial and later period Omicron dominance identify populations still at risk. A retrospective comparison data 965 patients hospitalized during early Omicron's (EO, January-June 2022) with 897 from a (LO, July 2022-April 2023) SARSTer database was performed. Patients LO, compared EO, were older, had better condition on admission, lower need for oxygen mechanical ventilation, less frequent lung involvement imaging, showed much...
Steatotic liver disease (SLD) can worsen the prognosis of other chronic diseases, including viral hepatitis. To compare SLD and non-SLD patients with hepatitis B virus (HBV) infection. The study included consecutive Caucasian treated nucleos(t)ide analogs (NA), entecavir or tenofovir, for a median (quartile 1-3) 6 (2-11) years evaluated between January 2023 June 2024. Of 273 in analysis, 86 were diagnosed SLD. Men dominated overall population, but their percentage was higher group (77.9% vs....
Difficult-to-treat populations with chronic hepatitis C (CHC), in the era of interferon treatment, included patients liver cirrhosis, kidney impairment, treatment-experienced individuals, and those coinfected human immunodeficiency virus. The current study aimed to determine whether, direct-acting antivirals (DAA), there are still that difficult-to-treat. all consecutive chronically infected virus (HCV) who started interferon-free therapy between July 2015 December 2020 Department Infectious...
ARTICLE HBV coinfection in HCV patients treated with DAA 1 HBV. 1,2Nearly 2 billion people globally have been exposed to an infection, as indicated by the presence of antibodies virus core antigen. Although and are phylogenetically distant pathogens, they share a similar transmission route, which increases odds coinfection.The rate at this phenomenon
It is estimated that 58 million people worldwide are infected with the hepatitis C virus (HCV). Patients severe psychiatric disorders could not be treated previously available interferon-based therapies due to their unfavorable side effect profile. This has changed introduction of direct-acting antivirals (DAA), although real-life tolerance and effectiveness in patients different remain demonstrated.To evaluate safety DAA various mental illnesses.This was a retrospective observational study...
Pangenotypic therapies for infections with hepatitis C virus (HCV), although universal and highly effective, entail a risk of treatment failure.
Continuous evaluation of real-world treatment effectiveness COVID-19 medicines is required due to the ongoing evolution SARS-CoV-2 and possible emergence resistance. Therefore, this study aimed analyze, in a retrospective manner, outcomes patients hospitalized with during pandemic waves dominated by Delta Omicron variants treated remdesivir (RDV) (n = 762) comparison demographically clinically matched group not any antivirals 1060). A logistic regression analysis revealed that RDV was...
Despite the excellent effectiveness of direct-acting antivirals (DAA) in treatment hepatitis C virus (HCV) infection, still a few percent patients fail therapy. The study aimed to determine triple vs double rescue such population.
Abstract Background The real-world effectiveness of molnupiravir (MOL) during the dominance Omicron SARS-CoV-2 lineage is urgently needed since available data relates to period circulation other viral variants. Therefore, this study assessed efficacy MOL in patients hospitalized for COVID-19 a clinical practice wave infections. Methods Among 11822 after 1 March 2020 and included SARSTer national database, 590 were treated between January 31 April 2022, variant. was administered 203 patients,...
Abstract Eliminating hepatitis C virus (HCV) infection in the population of women reproductive age is important not only for health themselves but also newborns. This study aimed to evaluate implementation this goal by analysing effectiveness contemporary therapy a large cohort from everyday clinical practice along with identifying factors reducing therapeutic success. The analysed consisted 7861 patients, including 3388 aged 15–49, treated 2015–2022 26 hepatology centres. Data were...
ABSTRACT To date, the effectiveness of direct‐acting antivirals (DAAs) discontinued before 4 weeks has not been analysed in routine clinical practice. The study aimed to determine whether such a short therapy will enable achieving sustained virological response under real‐world experience. population 97 patients who DAA and had data enabling analysis patient disease characteristics, assessment treatment was selected from 16,815 registered EpiTer‐2 database. most common reason for...
Background: Analyzing hospitalizations of patients with hepatitis C virus (HCV) infection is essential for an effective action plan to eliminate as a public health threat. This study aimed explore trends in HCV and factors related these hospitalizations. Methods: 11-year retrospective (2012–2022) explored Poland based on data from the Nationwide General Hospital Morbidity Study. Results: The mean age individuals was 55 years, hospitalization rates among men women 15.5 13.7 per 100,000...
The introduction of the direct-acting antivirals (DAA) has substantially improved effectiveness therapy in patients with chronic hepatitis C. We aimed to compare efficacy pangenotypic and genotype-specific DAA cohort genotype (GT) four HCV monoinfection HIV coinfection. A total 662 GT4-infected treated 2015-2020-of whom 168 (25.3%) were coinfected HIV, selected from retrospective EpiTer-2 database-were enrolled analysis. Among HIV-coinfected patients, 54% (90) regimens 46% (78) options,...
epidemiology, hepatitis C virus, interferon -free therapyAbsTRACT INTROduCTION The highly effective and safe (IFN)-free options were a breakthrough in the treatment of patients infected with virus (HCV).ObjECTIvEs current analysis was designed to evaluate changes patient profile antiviral characteristics over time. PATIENTs ANd mEThOdsThe study population consisted 963 consecutive HCV -infected who started IFN regimens between July 2015 December 2020 Department Infectious Diseases Kielce,...
Continuous evaluation of real-world treatment effectiveness COVID-19 medicines is required due to the ongoing evolution SARS-CoV-2 and possible emergence resistance. Therefore, this study aimed analyze outcomes in patients hospitalized with during pandemic waves dominated by Delta Omicron variants treated remdesivir (RDV) (n=762) comparison demographically clinically matched group not any antivirals (n=1060). During wave, RDV-treated revealed 2-fold lower mortality (10.8 vs. 23.2%,...
The study aimed to assess the phenomenon of achieving sustained virologic response (SVR) in patients with detectable ribonucleic acid (RNA) hepatitis C virus (HCV) at end treatment (ET) direct-acting antivirals (DAA), find how this is affected by type regimen, and experiencing differed from non-responders HCV RNA ET. included all consecutive ET selected EpiTer-2 database, a retrospective national multicentre project evaluating antiviral HCV-infected 2015–2023. Of 16106 treated IFN-free...